Ad
related to: 2022 fda new drug approvals
Search results
Results From The WOW.Com Content Network
A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients. ... The new drug is intended for treatment of moderate to severe acute pain ...
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx. FDA approves first new type of ...
The drug, suzetrigine, received the FDA's official stamp of approval Thursday to be sold as a 50-milligram prescription pill taken every 12 hours, according to a press release.
Mavacamten was approved for medical use in the United States in April 2022. [ 8 ] [ 12 ] [ 13 ] [ 14 ] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication . [ 15 ] [ 16 ]
Tirzepatide was approved for treatment of diabetes in the United States in May 2022, [9] [13] in the European Union in September 2022, [11] in Canada in November 2022, [19] and in Australia in December 2022. [2] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Avalglucosidase alfa was approved for medical use in the European Union in June 2022. [8] [14] The U.S. Food and Drug Administration (FDA) granted the application for avalglucosidase alfa fast track, priority review, breakthrough therapy, and orphan drug designations. [7] [15] The FDA granted the approval of Nexviazyme to Genzyme Corporation. [7]
The U.S. Food and Drug Administration's approval makes the drug, chemically known as semaglutide, to become the first GLP-1 treatment option for people with type 2 diabetes and CKD.
Efgartigimod alfa as a drug is an antibody fragment that binds to the neonatal Fc receptor. When this binding happens, the IgG recycling process is blocked. The amount of circulating IgG decreases and therefore prevents the acetylcholine receptors from being degraded by the autoantibodies that are responsible for the myasthenia gravis.
Ad
related to: 2022 fda new drug approvals